Marc S. Ernstoff
Experienced in Bone Tumor

Dr. Marc S. Ernstoff

Oncology
5014 Judicial Way, 
Frederick, MD 
Experienced in Bone Tumor
5014 Judicial Way, 
Frederick, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Ernstoff is an Oncologist in Frederick, Maryland. Dr. Ernstoff is rated as an Experienced provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, and Urothelial Cancer.

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Bone Tumor.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5014 Judicial Way, Frederick, MD 21703

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Other, Drug
Study Drug: Avelumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
Enrollment Status: Suspended
Publish Date: July 02, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Pembrolizumab, Propranolol Hydrochloride
Study Phase: Phase 1/Phase 2
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
Enrollment Status: Completed
Publish Date: February 13, 2025
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Procedure, Drug, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

142 Total Publications

Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV Biomarkers.
Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV Biomarkers.
Journal: Cancers
Published: June 18, 2025
Similar Doctors
Distinguished in Bone Tumor
Dr. Christian F. Meyer
Oncology
Distinguished in Bone Tumor
Dr. Christian F. Meyer
Oncology

Johns Hopkins University

601 N Caroline St, 
Baltimore, MD 
 (47.2 miles away)
410-955-5080
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christian Meyer is an Oncologist in Baltimore, Maryland. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Bone Tumor. Dr. Meyer is currently accepting new patients.

Distinguished in Bone Tumor
Dr. Ralph V. Boccia
Hematology Oncology | Oncology | Hematology
Distinguished in Bone Tumor
Dr. Ralph V. Boccia
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
 (29.9 miles away)
301-571-0019
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ralph Boccia is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Boccia is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Bone Tumor, Anemia, Iron Deficiency Anemia, Multiple Myeloma, and Splenectomy. Dr. Boccia is currently accepting new patients.

Distinguished in Bone Tumor
Dr. Patrick J. Mansky
Oncology | Pediatric Hematology Oncology
Distinguished in Bone Tumor
Dr. Patrick J. Mansky
Oncology | Pediatric Hematology Oncology

Frederick Health Medical Group LLC

1562 Opossumtown Pike, 
Frederick, MD 
 (6.0 miles away)
240-215-6310
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Mansky is an Oncologist and a Pediatric Hematologist Oncology provider in Frederick, Maryland. Dr. Mansky is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Melanoma. Dr. Mansky is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ernstoff's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile